Purple Biotech (PPBT)
(Delayed Data from NSDQ)
$6.89 USD
-0.09 (-1.29%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $6.78 -0.11 (-1.60%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Purple Biotech Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 1 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 22 | 23 | 18 | 14 | 8 |
Income After Depreciation & Amortization | -22 | -23 | -18 | -13 | -7 |
Non-Operating Income | 4 | 1 | 0 | -15 | 2 |
Interest Expense | 2 | 0 | 0 | 0 | 0 |
Pretax Income | -20 | -22 | -18 | -28 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -20 | -22 | -18 | -28 | -6 |
Extras & Discontinued Operations | 0 | 0 | -1 | 0 | 0 |
Net Income (GAAP) | -20 | -22 | -18 | -28 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -22 | -22 | -18 | -12 | -7 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -22 | -23 | -18 | -13 | -7 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 22.13 | 18.08 | 17.57 | 11.50 | 1.94 |
Diluted EPS Before Non-Recurring Items | -1.09 | -1.08 | -1.01 | -1.08 | -3.00 |
Diluted Net EPS (GAAP) | -0.90 | -1.20 | -1.05 | -2.44 | -3.00 |
Fiscal Year end for Purple Biotech Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 3.46 | 4.46 | 6.27 | 5.75 | 5.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.46 | -4.46 | -6.27 | -5.75 | -5.14 |
Non-Operating Income | 1.07 | 0.70 | -0.12 | 0.71 | 0.12 |
Interest Expense | 0.02 | 0.02 | 1.97 | 0.02 | 0.15 |
Pretax Income | -2.42 | -3.78 | -4.86 | -5.06 | -5.16 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | -0.01 | -0.02 | -0.03 | -0.02 | -0.02 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.42 | -3.78 | -4.86 | -5.06 | -5.16 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.41 | -3.76 | -4.83 | -5.04 | -5.14 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 27.53 | 27.11 | 25.79 | 21.84 | 21.01 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.16 | -0.32 | -0.23 | -0.25 |
Diluted Net EPS (GAAP) | -0.09 | -0.14 | -0.17 | -0.23 | -0.25 |